NasdaqGS:XERSPharmaceuticals
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Q4 2025 Earnings Beat
Xeris Biopharma Holdings (XERS) drew fresh investor attention after reporting fourth quarter 2025 earnings per share of US$0.06 on revenue of US$85.8 million, both above prior projections and supported by a reiteration of positive analyst views.
See our latest analysis for Xeris Biopharma Holdings.
At a share price of US$6.05, Xeris Biopharma’s recent 8.04% 7 day share price return and 4.13% 30 day share price return contrast with a 17.69% decline year to date. At the same time, the 37.19% 1...